MCM
UTHR icon

Mazama Capital Management’s United Therapeutics UTHR Stock Holding History

Mazama Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,254
Closed -$481K – 284
2013
Q4 		$481K Buy
+4,254
New +$384K 0.24% 131

Other funds holding UTHR

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Mazama Capital Management's UTHR Position: Q1 2014 in Review

Mazama Capital Management sold out of United Therapeutics (UTHR) in Q1 2014, closing a stake of 4,254 shares — an estimated $481K sold.

Mazama Capital Management first reported a position in UTHR in Q4 2013 and held it in 1 quarter. The position peaked at $481K in Q4 2013. 308 funds tracked by Wall St. Rank hold UTHR as of Q1 2014.

  • Mazama Capital Management reported no remaining United Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Mazama Capital Management sold 4,254 United Therapeutics shares in Q1 2014, an estimated $481K.
  • Mazama Capital Management first reported a position in United Therapeutics in Q4 2013 and held it in 1 quarter.
  • Mazama Capital Management's United Therapeutics position peaked at $481K in Q4 2013.
  • 308 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2014.

Based on Mazama Capital Management's 13F filing for Q1 2014, filed 3 Apr 2014.